玻璃体切除术联合视网膜下注射重组组织型纤溶酶原激活剂治疗伴或不伴玻璃体积血的黄斑下出血
研究纳入64例黄斑下出血患者的64只眼,行玻璃体切除术联合视网膜下注射重组组织型纤溶酶原激活剂,伴玻璃体积血组和不伴玻璃体积血组最佳矫正视力均显著改善,47只眼(73.43%)黄斑下出血完全移位,首次治疗、早期手术和较年轻年龄与更好的最终最佳矫正视力显著相关。
要点
- 伴玻璃体积血组最佳矫正视力从2.27±0.40改善至1.25±0.70 logMAR,不伴玻璃体积血组从1.76±0.55改善至0.85±0.65 logMAR。
- 47只眼(73.43%)黄斑下出血完全移位。
- 首次治疗、早期手术和较年轻年龄与更好的最终最佳矫正视力显著相关(B=0.502、0.303、0.021,均P<0.05)。
核心结论
- 玻璃体切除术联合视网膜下注射重组组织型纤溶酶原激活剂是伴或不伴玻璃体积血的黄斑下出血患者的有效治疗方法。
研究设计与样本
- 研究纳入64例黄斑下出血患者的64只眼,行玻璃体切除术联合视网膜下注射重组组织型纤溶酶原激活剂,分析最佳矫正视力、黄斑下出血移位和术后并发症,采用多变量线性回归确定最终最佳矫正视力的预测因素。
主要发现
- 伴玻璃体积血组26只眼最佳矫正视力从2.27±0.40改善至1.25±0.70 logMAR,不伴玻璃体积血组38只眼从1.76±0.55改善至0.85±0.65 logMAR。
- 47只眼(73.43%)黄斑下出血完全移位。
- 术后并发症包括复发性黄斑下出血(4.69%)、复发性玻璃体积血(10.94%)、孔源性视网膜脱离(3.13%)和视网膜前膜(4.68%)。
- 首次治疗、早期手术和较年轻年龄与更好的最终最佳矫正视力显著相关(B=0.502、0.303、0.021,均P<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate the outcomes and prognostic factors of pars plana vitrectomy combined with subretinal injection of recombinant tissue plasminogen activator for submacular hemorrhage (SMH) patients with or without vitreous hemorrhage (VH). METHODS: Sixty-four eyes of 64 patients with SMH underwent pars plana vitrectomy with subretinal injection of recombinant tissue plasminogen activator. Best-corrected visual acuity, SMH displacement, and postoperative complications were analyzed. Predictive factors of the final best-corrected visual acuity were determined using multivariant linear regression. RESULTS: There were 26 eyes with VH and 38 eyes without VH best-corrected visual acuity significantly improved in both VH group (from 2.27 ± 0.40 to 1.25 ± 0.70 logarithm of the minimum angle of resolution) and non-VH group (from 1.76 ± 0.55 to 0.85 ± 0.65 logarithm of the minimum angle of resolution). Complete displacement of SMHs was observed in 47 (73.43%) eyes. Postoperative complications included recurrent SMH (4.69%), recurrent VH (10.94%), rhegmatogenous retinal detachment (3.13%), and epiretinal membrane (4.68%). Treatment-naive condition, early surgery, and younger age were significantly associated with better final best-corrected visual acuity ( B = 0.502, 0.303, and 0.021, respectively, with all P < 0.05). CONCLUSION: Pars plana vitrectomy combined with subretinal recombinant tissue plasminogen activator injection is an effective treatment for SMH patients with and without VH.
引用
- Shi T, Wen J, Xia H, et al. VITRECTOMY WITH SUBRETINAL INJECTION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR FOR SUBMACULAR HEMORRHAGE WITH OR WITHOUT VITREOUS HEMORRHAGE. Retina. 2024. PMID: 38452260. doi:10.1097/IAE.0000000000004093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。